BEUDAMED
    FDA PMA FDA Class 3 Approved 🇺🇸 United States

    Immunohistochemistry Test, Dna Mismatch Repair (Mmr) Protein Assay

    PMA: P210001 · Supplement: S013 · Decision Dec 18, 2024
    View on FDA
    Classifications
    1
    FEI Numbers
    1
    Registration Numbers
    1

    Basic Information

    Device Name
    Immunohistochemistry Test, Dna Mismatch Repair (Mmr) Protein Assay
    Trade Name
    VENTANA MMR RxDx Panel
    PMA Number
    P210001
    Supplement Number
    S013
    Device Class
    FDA Class 3
    Product Code
    QNH
    Generic Name
    Immunohistochemistry test, DNA mismatch repair (MMR) Protein assay
    Regulation Number
    864.1860
    Medical Specialty
    Hematology
    Advisory Committee
    Pathology
    Decision
    Approved
    Decision Code
    APPR
    Decision Date
    December 18, 2024
    Date Received
    July 17, 2024
    Supplement Type
    Normal 180 Day Track
    Supplement Reason
    Labeling Change - Indications/instructions/shelf life/tradename
    Expedited Review
    N

    Advisory Committee Statement

    approval to include a companion diagnostic indication to identify adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient, who are eligible for treatment with IMFINZI® (durvalumab) in combination with carboplatin and paclitaxel, followed by IMFINZI® (durvalumab) as a single agent.

    Classifications

    This FDA Pre-Market Approval entry is associated with 1 FDA classification via its product code.

    Product Code Device Name
    QNH Immunohistochemistry Test, Dna Mismatch Repair (Mmr) Protein Assay